durvalumab + carboplatin + etoposide

Durvalumab + carboplatin + etoposide is a combination regimen consisting of a **monoclonal antibody checkpoint inhibitor** (durvalumab) and two **cytotoxic chemotherapy agents** (carboplatin and etoposide). **Durvalumab** is an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody that blocks the interaction between PD-L1 and PD-1/CD80, unleashing an immune response against tumor cells. **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis, while **etoposide** inhibits topoisomerase II, preventing DNA replication and leading to cell death. This combination is indicated and approved as first-line therapy for **extensive-stage small cell lung cancer (ES-SCLC)**, and is given as induction therapy (all three drugs) followed by maintenance durvalumab monotherapy[3][4][1][5][6][7].

Brand names

Imfinzi

Other names

durvalumab + carboplatin + etoposidedurvalumab + CBDCA + ETP